Quality-adjusted life-years accrued with cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial

被引：0
|
作者：
Strasser, S. [1 ,2 ]
Abou-Alfa, G. [8 ]
Mollon, P. [3 ]
Meyer, T. [5 ]
Cheng, A. [6 ,7 ]
El-Khoueiry, A. [9 ]
Kelley, R. [10 ]
Baron, A. [11 ]
Benzaghou, F. [4 ]
Valcheva, V. [3 ]
Hazra, S. [12 ]
Mangeshkar, M. [12 ]
Freemantle, N. [5 ]
机构：
[1] Royal Prince Alfred Hosp, Sydney, NSW, Australia
[2] Univ Sydney, Sydney, NSW, Australia
[3] Ipsen Pharma SAS, Boulogne, France
[4] Ipsen Innovat, Les Ulis, France
[5] UCL, London, England
[6] Natl Taiwan Univ Hosp, Taipei, Taiwan
[7] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[9] USC Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[10] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[11] Calif Pacific Med Ctr, San Francisco, CA USA
[12] Exelixis Inc, San Francisco, CA USA
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2019年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
444
引用
收藏
页码：43 / 43
页数：1
相关论文
共 50 条
  • [41] QUALITY-ADJUSTED LIFE YEARS - REPLY
    RICHARDSON, J
    SCHWARTZ, S
    AUSTRALIAN JOURNAL OF PUBLIC HEALTH, 1994, 18 (02): : 227 - 228
  • [42] Putting the quality into quality-adjusted life years
    Oliver, A
    JOURNAL OF PUBLIC HEALTH MEDICINE, 2003, 25 (01): : 8 - 12
  • [43] THE RANKING PROPERTIES OF HEALTHY-YEARS EQUIVALENTS AND QUALITY-ADJUSTED LIFE-YEARS UNDER CERTAINTY AND UNCERTAINTY
    JOHANNESSON, M
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 1995, 11 (01) : 40 - 48
  • [44] The quality-adjusted life-years loss due to serogroup B invasive meningococcal disease in Spain
    Garcia, Andrea
    Vallejo-Aparicio, Laura A.
    Begum, Najida
    Nikitas, Georgios
    Gonzalez-Inchausti, Carmen
    de Gomensoro, Eduardo
    VACCINE, 2024, 42 (22)
  • [45] The Impact of the Approach to Accounting for Age and Sex in Economic Models on Predicted Quality-Adjusted Life-Years
    Lee, Dawn
    Hart, Rose
    Burns, Darren
    Mccarthy, Grant
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2025, 23 (01) : 131 - 140
  • [46] Quantifying the Burden of Hyperphagia in Prader-Willi Syndrome Using Quality-Adjusted Life-years
    Lavelle, Tara A.
    Crossnohere, Norah L.
    Bridges, John F. P.
    CLINICAL THERAPEUTICS, 2021, 43 (07) : 1164 - +
  • [47] Accrued Cost Savings of a Free Clinic Using Quality-Adjusted Life Years Saved and Return on Investment
    Sanders, Jim
    Lacey, Marcus
    Guse, Clare E.
    JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2017, 30 (04) : 505 - 512
  • [48] Association of adverse events with efficacy outcomes for cabozantinib in patients with advanced hepatocellular carcinoma in the Phase III CELESTIAL trial
    Strasser, S.
    Abou-Alfa, G.
    Meyer, T.
    Cheng, A.
    Cicin, I.
    Bolondi, L.
    Klumpen, H.
    Chan, S.
    Zagonel, V.
    Milwee, S.
    Dubey, S.
    Kelley, R.
    El-Khoueiry, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 33 - 34
  • [49] WILLINGNESS TO PAY FOR QUALITY-ADJUSTED LIFE YEARS IN PATIENTS WITH DIABETE
    Moradi, N.
    Rashidian, A.
    VALUE IN HEALTH, 2015, 18 (07) : A617 - A617
  • [50] How to Value a Life Without Limits: Quantifying Suffering With Quality-Adjusted Life-Years in Social Anxiety Disorder
    Havlik, John L.
    Rhee, Taeho Greg
    JOURNAL OF CLINICAL PSYCHIATRY, 2024, 85 (02)
12345